Vaderis
Manufacturing · Switzerland · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Bäumleingasse 18, Basel, Basel-City, 405...Phone Number
+41 795922005Website
www.vaderis.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Vaderis
Vaderis Therapeutics is a biotech company focused on developing breakthrough therapies for patients with Hereditary Hemorrhagic Telangiectasia (HHT) and other rare vascular diseases. The company is driven by a commitment to rigorous science and aims to transform deep biological insights into targeted therapies that address unmet medical needs. Their mission is to provide real solutions for patients who have long faced uncertainty due to the absence of approved treatments. Vaderis Therapeutics strives to create a future defined by stability, clarity, and hope for families affected by these complex conditions.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Vaderis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Vaderis recently announced quarterly report
Funding: Get notified immidiatlly once Vaderis has new funding data
Check out if Vaderis is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Vaderis
Click to see if Vaderis had a recent Job posting/layoffs
Check if Vaderis has recently received funding, and reach out quickly before it becomes old news!
Vaderis, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Vaderis launches new products
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Vaderis
Find 2 more new buyers
Company Profile Activity
Activity Insights
Vaderis is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Vaderis is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Vaderis.
Vaderis financials insights
Gather financial insights about Vaderis, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2026
Series B
$152M
Vaderis Tech Stack
A closer look at the technologies used by Vaderis
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
New Hire
Executive Move
Azmi Nabulsi has recently joined the organization as Chief Executive Officer & President. Previously, Nabulsi served as Chief Operating Officer for Phathom Pharmaceuticals.
Executive Moves, New Hire
New Hire
Executive Move
Vaderis has announced that Azmi Nabulsi has joined the organization as Chief Executive Officer & President.
Executive Moves, New Hire
Left Company
Executive Move
Executive Moves, Left Company
Vaderis News & Media
EQT Life Sciences participates in Vaderis Therapeutics' USD 152 million Series B financing
STOCKHOLM, Aug. 11, 2026 /PRNewswire/ -- EQT Life Sciences is investing USD 17.5 million in Vaderis Therapeutics as part of the Swiss company's USD 152 million Series B financing The financing will support the initiation of the global Phase 3 HEROIC study evaluating engasertib, a...Vaderis Therapeutics AG | - WebDisclosure
Vaderis Therapeutics closes $152 million Series B financing and starts global Phase 3 HEROIC study of engasertib for Hereditary Hemorrhagic Telangiectasia, marking a significant advancement in developing a therapy for the rare vascular diseaseVaderis Therapeutics Announces Oversubscribed $152 Million Series B Financing and Initiation of the Global Phase 3 HEROIC Study of Engasertib for Hereditary Hemorrhagic Telangiectasia
$152 million Series B financing by private placement to select investors, co-led by Life Sciences at Goldman Sachs Alternatives and TCGX, with participation from Omega Funds, EQT Life Sciences, Perceptive Advisors, Kalehua Capital, and existing investors Medicxi and Droia Provides the...Vaderis Therapeutics Announces Oversubscribed $152 Million Series B Financing and Initiation of the Global Phase 3 HEROIC Study of Engasertib for Hereditary Hemorrhagic Telangiectasia
$152 million Series B financing by private placement to select investors, co-led by Life Sciences at Goldman Sachs Alternatives and TCGX, with participation from Omega Funds, EQT Life Sciences, Perceptive Advisors, Kalehua Capital, and existing investors Medicxi and Droia Provides the...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Vaderis
Sign Up For FreeTo access detailed company insights
Vaderis Therapeutics is a biotech company focused on developing breakthrough therapies for patients with Hereditary Hemorrhagic Telangiectasia (HHT) and other rare vascular diseases. The company is driven by a commitment to rigorous science and aims to transform deep biological insights into targeted therapies that address unmet medical needs. Thei... Read More
